공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

항생제 시장 규모, 점유율, 동향 분석 : 의약품 클래스(세팔로스포린, 페니실린, 플루오로퀴놀론, 매크로라이드, 카르바페넴, 아미노글리코시드, 술폰아미드, 7-ACA), 작용기서, 지역별 예측(2021-2028년)

Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-ACA), By Action Mechanism, And Segment Forecasts, 2021 - 2028

리서치사 Grand View Research, Inc.
발행일 2021년 02월 상품 코드 989696
페이지 정보 영문 120 Pages
가격
US $ 5,950 ₩ 6,725,000 Unprintable PDF (Single User License)
US $ 6,950 ₩ 7,855,000 Printable PDF (5-User License)
US $ 8,950 ₩ 10,116,000 Printable PDF (Enterprise License)


항생제 시장 규모, 점유율, 동향 분석 : 의약품 클래스(세팔로스포린, 페니실린, 플루오로퀴놀론, 매크로라이드, 카르바페넴, 아미노글리코시드, 술폰아미드, 7-ACA), 작용기서, 지역별 예측(2021-2028년) Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-ACA), By Action Mechanism, And Segment Forecasts, 2021 - 2028
발행일 : 2021년 02월 페이지 정보 : 영문 120 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 항생제 시장 규모는 예측 기간 중 4.5%의 CAGR로 추이하며, 2028년에는 579억 9000만 달러 규모로 성장할 것으로 예측됩니다. 항생제의 높은 사용률, 환자 및 의료 종사자의 인식 향상, 새로운 감염증 치료제 R&D에서 규제기관의 관여 등의 요인이 이 시장의 성장을 촉진하고 있습니다.

세계의 항생제 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 법규제 환경, 시장 규모의 추이·예측, 작용기서·의약품 클래스·지역/주요 국가 등 각종 부문별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 조사 방법·조사 범위

제2장 개요

제3장 시장 가변 요인·동향·전망

  • 시장 역학
  • 보급·성장 전망 지도제작
  • 사업 환경 분석 툴
  • 가격 분석

제4장 규제·정치적 영향요인

  • 북미
  • 유럽
  • 아시아태평양

제5장 시장 예측·동향 분석 : 작용기서별

  • 대시보드
  • 시장 규모의 추이·예측
  • 시장 점유율 실적·예측
  • 세포벽 합성 저해제
  • 단백질 합성 저해제
  • DNA 합성 저해제
  • RNA 합성 저해제
  • 미콜산 저해제
  • 기타

제6장 시장 예측·동향 분석 : 의약품 클래스별

  • 대시보드
  • 시장 규모의 추이·예측
  • 시장 점유율 실적·예측
  • 세팔로스포린
  • 페니실린
  • 플루오로퀴놀론
  • 매크로라이드
  • 카르바페넴
  • 아미노글리코시드
  • 술폰아미드
  • 7-ACA
  • 기타

제7장 시장 예측·동향 분석 : 지역·주요 국가별

  • 대시보드
  • 시장 규모의 추이·예측
  • 시장 점유율 실적·예측
  • 북미
    • 미국
  • 캐나다
  • 유럽
    • 독일
    • 영국
    • 스페인
    • 프랑스
    • 이탈리아
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
  • 중동·아프리카
    • 남아프리카공화국
    • 아랍에미리트
    • 사우디아라비아

제8장 경쟁 환경·벤더 구도

  • 참여 사업자 분류
  • 전략 지도제작
  • 전략적 프레임워크
  • 기업 개요
KSA 21.02.23

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Approved Treatment for cIAI
  • Table 4 Approved Treatment for cUTI
  • Table 5 Approved Treatment for Gonorrhea
  • Table 6 Approved Treatment for ABSSSI
  • Table 7 Approved Treatment for CDI
  • Table 8 Approved Treatment for CAP
  • Table 9 Approved Treatment for HAP
  • Table 10 Examples of Cephalosporin
  • Table 11 Examples of Penicillin
  • Table 12 North America Antibiotics Market, By Country, 2017 - 2028 (USD Million)
  • Table 13 North America Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 14 North America Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 15 U.S. Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 16 U.S. Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 17 Canada Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 18 Canada Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 19 Europe Antibiotics Market, By Country, 2017 - 2028 (USD Million)
  • Table 20 Europe Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 21 Europe Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 22 U.K. Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 23 U.K. Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 24 Germany Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 25 Germany Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 26 France Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 27 France Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 28 Spain Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 29 Spain Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 30 Italy Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 31 Italy Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 32 Asia Pacific Antibiotics Market, By Country, 2017 - 2028 (USD Million)
  • Table 33 Asia Pacific Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 34 Asia Pacific Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 35 Japan Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 36 Japan Antibiotics Market, By Drug Class 2017 - 2028 (USD Million)
  • Table 37 China Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 38 China Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 39 India Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 40 India Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 41 South Korea Antibiotics Market, By Action Mechanism 2017 - 2028 (USD Million)
  • Table 42 South Korea Antibiotics Market, By Drug Class 2017 - 2028 (USD Million)
  • Table 43 Thailand Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 44 Thailand Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 45 Latin America Antibiotics Market, By Country, 2017 - 2028 (USD Million)
  • Table 46 Latin America Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 47 Latin America Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 48 Brazil Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 49 Brazil Antibiotics Market, By Drug Class 2017 - 2028 (USD Million)
  • Table 50 Mexico Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 51 Mexico Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 52 Argentina Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 53 Argentina Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 54 Middle East & Africa Antibiotics Market, By Country, 2017 - 2028 (USD Million)
  • Table 55 Middle East & Africa Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 56 Middle East & Africa Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 57 South Africa Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 58 South Africa Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 59 Saudi Arabia Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 60 Saudi Arabia Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)
  • Table 61 UAE Antibiotics Market, By Action Mechanism, 2017 - 2028 (USD Million)
  • Table 62 UAE Antibiotics Market, By Drug Class, 2017 - 2028 (USD Million)

List of Figures

  • Fig. 1 Antibiotics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Antibiotics market snapshot
  • Fig. 10 Antibiotics market driver impact
  • Fig. 11 Antibiotics market restraint impact
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Ansoff matrix
  • Fig. 16 Antibiotics market: action mechanism outlook and key takeaways
  • Fig. 17 Antibiotics market: action mechanism movement analysis
  • Fig. 18 Action mechanism segment dashboard
  • Fig. 19 Cell wall synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 20 Protein synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 21 DNA synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 22 RNA synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 23 Mycolic acid inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 24 Others market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 25 Antibiotics market: Drug class outlook and key takeaways
  • Fig. 26 Antibiotics market: Drug class movement analysis
  • Fig. 27 Drug class segment dashboard
  • Fig. 28 Cephalosporin market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 29 Penicillin market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 30 Fluoroquinolone market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 31 Macrolide market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 32 Carbapenem market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 33 Aminoglycoside market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 34 Sulfonamide market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 35 7-ACA market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 36 Others market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 37 Antibiotics market: Regional outlook and key takeaways
  • Fig. 38 Regional outlook, 2020 & 2028 (USD Million)
  • Fig. 39 Regional market dashboard
  • Fig. 40 North America
  • Fig. 41 North America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 42 U.S.
  • Fig. 43 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 44 Canada
  • Fig. 45 Canada market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 46 Europe
  • Fig. 47 Europe market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 48 Germany
  • Fig. 49 Germany market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 50 U.K.
  • Fig. 51 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 52 Spain
  • Fig. 53 Spain market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 54 France
  • Fig. 55 France market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 56 Italy
  • Fig. 57 Italy market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 58 Asia Pacific
  • Fig. 59 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 60 Japan
  • Fig. 61 Japan market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 62 China
  • Fig. 63 China market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 64 India
  • Fig. 65 India market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 66 South Korea
  • Fig. 67 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 68 Thailand
  • Fig. 69 Thailand market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 70 Latin America
  • Fig. 71 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 72 Brazil
  • Fig. 73 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 74 Mexico
  • Fig. 75 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 76 Argentina
  • Fig. 77 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 78 Middle East & Africa
  • Fig. 79 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 80 South Africa
  • Fig. 81 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 82 UAE
  • Fig. 83 UAE market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 84 Saudi Arabia
  • Fig. 85 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
  • Fig. 86 Participant categorization
  • Fig. 87 Strategy mapping
  • Fig. 88 Strategic framework
  • Fig. 89 Company market share analysis

Antibiotics Market Growth & Trends

The global antibiotics market size is expected to reach USD 57.99 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.5% from 2021 to 2028. High usage of antibiotics and inappropriate prescription behavior of antibiotic drugs worldwide are the major factors anticipated to drive the market. Moreover, rising awareness among patients and healthcare professionals and increasing involvement of regulatory bodies in the R&D activities of new therapies to treat infectious diseases are expected to propel the market growth over the forecast period.

An increasing number of public-private collaborations, wherein funding and innovative R&D approaches are provided by public agencies to firms developing antibiotics, is expected to boost the product pipeline. For instance, in December 2018, Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited announced an agreement with GARDP for the development of novel antibacterial compounds.

Betterment in the approval process of antibiotic drugs is expected to boost the market growth over the forecast period. In February 2020, Merck received acceptance for a review of supplemental New Drug Application (sNDA) from the U.S. FDA for RECARBRIO (imipenem, cilastatin, and relebactam) intended for HABP/VABP. This submission is anticipated to reinforce the continued dedication of the company to R&D pertaining to antibiotic therapies that address unmet medical needs.

Government reforms such as the Generating Antibiotics Incentives Now Act in the U.S. are projected to propel market growth in the coming years. This is further expected to facilitate the development process of advanced drugs. According to the Pew Charitable Trusts, about 30% of the outpatient oral antibiotic drug prescriptions are unnecessary and most of these prescriptions are for disease conditions against which antibiotics are not significantly effective, such as non-bacterial infections and acute respiratory conditions.

The market is highly competitive and major market players have almost similar market share. Pharmaceutical players are adopting strategies, including mergers & acquisitions, collaborations, and strategic alliances, to gain a competitive advantage. The major pharmaceutical companies are collaborating for developing novel therapies to reduce the cost burden of the drug development process. In December 2019, Appili Therapeutics signed an agreement with Saptalis Pharmaceuticals for the reformulation of antibiotic metronidazole. According to the agreement, Saptalis will be responsible for manufacturing, marketing of ATI-1501 in the United States. Moreover, in October 2018, Paratek Pharmaceuticals, Inc. entered into a license agreement for the development and commercialization of Seysara (sarecyline) with Allergan.

A group of key pharmaceutical players has launched AMR Action Fund worth USD 1 billion in July 2020. This fund is expected to support the research of innovative and novel antibiotics and is formed in collaboration with the European Investment Bank, the Wellcome Trust, and the World Health Organization.

Due to the lack of commercial success for newly developed antimicrobial drugs, government and non-government bodies have adopted strategies to incentivize antibiotic drug R&D activities. For instance, the government in alliance with BARDA is supporting several companies to boost the R&D activities in new therapies for infectious diseases. BARDA has also been associated with pharmaceutical companies, such as GSK, Tetraphase, and Basilea Astra Zeneca. CARB-X is investing around USD 109 million to support the early-stage development of potential therapeutic candidates.

Antibiotics Market Report Highlights

  • By action mechanism, the cell wall synthesis inhibitors segment accounted for the largest share of 52.1% in 2020 and is anticipated to maintain its lead over the forecast period
  • Based on drug class, the cephalosporin segment held the second-largest share in 2020. Pipeline candidates in cephalosporin drug class such as Fetroja (cefiderocol), cefilavancin, and ceftobiprole are anticipated to drive the segment in the forecast period
  • The others' drug class segment is expected to grow at the fastest rate during the forecast period. The segment consists of various existing classes of antibiotics as well as some newly developed drugs, such as tetracycline, carbapenem, imidazole, peptides, lincosamides, and monoclonal antibodies
  • Asia Pacific was the largest regional market in 2020 and is expected to witness the fastest growth in the coming years owing to the rising consumption of antibiotics and high disease prevalence
  • North America emerged as the second-largest regional market in 2020 owing to government initiatives for the development of new therapies and better reimbursement scenario

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Action Mechanism
    • 1.1.2 Drug Class
    • 1.1.3 Regional Scope
    • 1.1.4 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: commodity flow approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3
    • 1.9.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Antibiotics Market Variables, Trends & Scope

  • 3.1 Market Dynamics
    • 3.1.1 Market Driver Analysis
    • 3.1.2 Development of Advanced Products
    • 3.1.3 Increasing Prevalence of Infectious Diseases
    • 3.1.4 Growing Collaborations for Development of Antibiotics
    • 3.1.5 Market Restraint Analysis
    • 3.1.6 High R&D Cost
    • 3.1.7 Development of Resistance against Antibiotics
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Business Environment Analysis Tools
    • 3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
    • 3.3.2 Porter's Five Forces Analysis
    • 3.3.3 Industry Analysis - Ansoff Matrix
  • 3.4 Pricing Analysis

Chapter 4 Regulatory & Political Forces

  • 4.1 North America
  • 4.2 Europe
  • 4.3 Asia Pacific

Chapter 5 Antibiotics Market - Segment Analysis, By Action Mechanism, 2017 - 2028 (USD Million)

  • 5.1 Action Mechanism Market Share Analysis, 2020 & 2028 (USD Million)
  • 5.2 Segment Dashboard
  • 5.3 Market Size & Forecasts and Trend Analysis, 2017 - 2028 (USD Million)
    • 5.3.1 Cell Wall Synthesis Inhibitors
      • 5.3.1.1 Cell wall synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
    • 5.3.2 Protein Synthesis Inhibitors
      • 5.3.2.1 Protein synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
    • 5.3.3 DNA Synthesis Inhibitors
      • 5.3.3.1 DNA synthesis inhibitors estimates and forecast, 2017 - 2028 (USD Million)
    • 5.3.4 RNA Synthesis Inhibitors
      • 5.3.4.1 RNA synthesis inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
    • 5.3.5 Mycolic Acid Inhibitors
      • 5.3.5.1 Mycolic acid inhibitors market estimates and forecast, 2017 - 2028 (USD Million)
    • 5.3.6 Others
      • 5.3.6.1 Others market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 6 Antibiotics Market - Segment Analysis, By Drug Class, 2017 - 2028 (USD Million)

  • 6.1 Drug Class Market Share Analysis, 2020 & 2028 (USD Million)
  • 6.2 Segment Dashboard
  • 6.3 Market Size & Forecasts and Trend Analysis, 2017 to 2028 (USD Million)
    • 6.3.1 Cephalosporin
      • 6.3.1.1 Cephalosporin market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.2 Penicillin
      • 6.3.2.1 Penicillin market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.3 Fluoroquinolone
      • 6.3.3.1 Fluoroquinolone market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.4 Macrolide
      • 6.3.4.1 Macrolide market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.5 Carbapenem
      • 6.3.5.1 Carbapenem market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.6 Aminoglycoside
      • 6.3.6.1 Aminoglycoside market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.7 Sulfonamide
      • 6.3.7.1 Sulfonamides market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.8 7-ACA
      • 6.3.8.1 7-ACA market estimates and forecast, 2017 - 2028 (USD Million)
    • 6.3.9 Others
      • 6.3.9.1 Others market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 7 Antibiotics Market - Segment Analysis, By Region, 2017 - 2028 (USD Million)

  • 7.1 Regional Market Share Analysis, 2020 & 2028 (USD Million)
  • 7.2 Regional Market Dashboard
  • 7.3 North America
    • 7.3.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.3.2 U.S.
      • 7.3.2.1 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.4 Canada
    • 7.4.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.5 Europe
    • 7.5.1 Europe market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.5.2 Germany
      • 7.5.2.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.5.3 U.K.
      • 7.5.3.1 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.5.4 Spain
      • 7.5.4.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.5.5 France
      • 7.5.5.1 France market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.5.6 Italy
      • 7.5.6.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.6 Asia Pacific
    • 7.6.1 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.6.2 Japan
      • 7.6.2.1 Japan market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.6.3 China
      • 7.6.3.1 China market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.6.4 India
      • 7.6.4.1 India market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.6.5 South Korea
      • 7.6.5.1 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.6.6 Thailand
      • 7.6.6.1 Thailand market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.7 Latin America
    • 7.7.1 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.7.2 Brazil
      • 7.7.2.1 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.7.3 Mexico
      • 7.7.3.1 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.7.4 Argentina
      • 7.7.4.1 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
  • 7.8 Middle East & Africa
    • 7.8.1 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.8.2 South Africa
      • 7.8.2.1 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.8.3 UAE
      • 7.8.3.1 UAE market estimates and forecast, 2017 - 2028 (USD Million)
    • 7.8.4 Saudi Arabia
      • 7.8.4.1 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)

Chapter 8 Competitive & Vendor Landscape

  • 8.1 Participant Categorization
    • 8.1.1 Innovators
    • 8.1.2 Market Leaders
  • 8.2 Strategy Mapping
    • 8.2.1 Key Strategies Chosen by Players in this Market Include:
      • 8.2.1.1 Launch of new products
      • 8.2.1.2 Acquisition
      • 8.2.1.3 Expansion
      • 8.2.1.4 Agreements, collaborations, partnerships
      • 8.2.1.5 Others (realignment, divestment, market penetration):
  • 8.3 Strategic Framework
    • 8.3.1 Key Company Market Share Analysis, 2020
  • 8.4 Company Profiles
    • 8.4.1 Allergan (AbbVie Inc.)
      • 8.4.1.1 Company overview
      • 8.4.1.2 Financial performance
      • 8.4.1.3 Product benchmarking
      • 8.4.1.4 Strategic initiatives
    • 8.4.2 Merck & Co., Inc
      • 8.4.2.1 Company overview
      • 8.4.2.2 Financial performance
      • 8.4.2.3 Product benchmarking
      • 8.4.2.4 Strategic initiatives
    • 8.4.3 Cumberland Pharmaceuticals, Inc.
      • 8.4.3.1 Company overview
      • 8.4.3.2 Financial performance
      • 8.4.3.3 Product benchmarking
      • 8.4.3.4 Strategic initiatives
    • 8.4.4 GlaxoSmithKline plc
      • 8.4.4.1 Company overview
      • 8.4.4.2 Financial performance
      • 8.4.4.3 Product pipeline
      • 8.4.4.4 Strategic initiatives
    • 8.4.5 Novartis AG
      • 8.4.5.1 Company overview
      • 8.4.5.2 Financial performance
      • 8.4.5.3 Product pipeline
      • 8.4.5.4 Strategic initiatives
    • 8.4.6 Melinta Therapeutics
      • 8.4.6.1 Company overview
      • 8.4.6.2 Product benchmarking
      • 8.4.6.3 Strategic initiatives
    • 8.4.7 Teva Pharmaceutical Industries Ltd.
      • 8.4.7.1 Company overview
      • 8.4.7.2 Financial performance
      • 8.4.7.3 Product benchmarking
    • 8.4.8 Nabriva Therapeutics plc
      • 8.4.8.1 Company overview
      • 8.4.8.2 Financial performance
      • 8.4.8.3 Product benchmarking
      • 8.4.8.4 Strategic initiatives
    • 8.4.9 Mylan N.V.
      • 8.4.9.1 Company overview
      • 8.4.9.2 Financial performance
      • 8.4.9.3 Product benchmarking
Back to Top
전화 문의
F A Q